Skip to main content
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2003 Nov 7;17(6):271–275. doi: 10.1002/jcla.10108

Chitotriosidase activity in plasma and mononuclear and polymorphonuclear leukocyte populations

Lorena Bouzas 1, J Carlos Guinarte 1, J Carlos Tutor 1,
PMCID: PMC6808134  PMID: 14614752

Abstract

In the general population, about 5% of individuals are homozygotic and 35% are heterozygotic carriers for chitotriosidase (ChT) deficiency. Activated macrophages are considered to be the main source of plasma ChT activity, which permits the biochemical characterization of homozygote deficients. However, in the case of detecting heterozygotic carriers, the results are often inconclusive. The activities of ChT in plasma and mononuclear (MN) and polymorphonuclear (PMN) leukocytes were determined in 169 control subjects (72 males and 97 females) with a mean age (± SD) of 47.5±9.7 years (range 18–96 years). The specific enzyme activity was in PMN leukocytes >MN leukocytes >plasma, with a highly significant partial correlation being found between the activities of ChT in plasma and PMN leukocytes (r=0.578, P<0.001). A significant correlation was found between the age of the patients studied and plasma ChT activity (r=0.568, P<0.001). No significant correlation was found for enzyme activities in MN (r=0.105) or in PMN leukocytes (r=0.043). The results obtained suggest that, in normal physiological conditions, PMN leukocytes may secrete ChT to the plasma. Although the activities of ChT in MN and PMN leukocytes are not affected by demographic factors, it is not possible to use them for the biochemical detection of ChT‐deficient heterozygotic carriers. J. Clin. Lab. Anal. 17:271–275, 2003. © 2003 Wiley‐Liss, Inc.

Keywords: chitotriosidase, mononuclear leukocytes, polymorphonuclear leukocytes, plasma, chitotriosidase deficiency

REFERENCES

  • 1. Renkema GH, Boot RG, Strijland A, et al. Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotiosidase. Eur J Biochem 1997;244:279–285. [DOI] [PubMed] [Google Scholar]
  • 2. Boot RG, Blommaart EFC, Swart E, et al. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 2001;276:6770–6778. [DOI] [PubMed] [Google Scholar]
  • 3. Hollak CEM, van Weely S, van Oers MHJ, Aerts JMFG. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288–1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Guo Y, He W, Boer AM, et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 1995;18:717–722. [DOI] [PubMed] [Google Scholar]
  • 5. Giraldo P, Cenarro A, Alfonso P, et al. Chitotriosidase genotype and plasma activity in patients with type 1 Gaucher's disease and their relatives (carriers and non carriers). Haematologica 2001;86:977–984. [PubMed] [Google Scholar]
  • 6. Casal JA, Lacerda L, Perez LF, Pinto RA, Sá Miranda MC, Tutor JC. Relationship between serum markers of monocyte/macrophage activation in type 1 Gaucher's disease. Clin Chem Lab Med 2002;40:52–55. [DOI] [PubMed] [Google Scholar]
  • 7. Barone R, Di Gregorio F, Romeo MA, Schiliro G, Pavone L. Plasma chitotriosidase activity in patients with β‐thalassemia. Blood Cells Mol Dis 1999;25:1–8. [DOI] [PubMed] [Google Scholar]
  • 8. Maccarone C, Pizzarelli G, Barone R, Musumeci S. Plasma chitotriosidase activity is a marker of recovery in transplanted patients affected by β‐thalassemia major. Acta Haematol 2001;105:109–110. [DOI] [PubMed] [Google Scholar]
  • 9. Barone R, Simpore J, Malaguarnera L, Pignatelli S, Musumeci S. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clin Chim Acta 2003;331:79–85. [DOI] [PubMed] [Google Scholar]
  • 10. Labadaridis J, Dimitriou E, Costalos C, et al. Serial chitotriosidase activity estimations in neonatal systemic candidiasis. Acta Paediatr 1998;87:605–606. [DOI] [PubMed] [Google Scholar]
  • 11. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998;273:25680–25685. [DOI] [PubMed] [Google Scholar]
  • 12. Canudas J, Cenarro A, Civeira F, et al. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid‐lowering agents, atorvastatin and bezafibrate. Metabolism 2001;50:447–450. [DOI] [PubMed] [Google Scholar]
  • 13. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JMFG. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995;270:26252–26256 [DOI] [PubMed] [Google Scholar]
  • 14. Czartoryska B, Fiszer U, Lugowska A. Chitotriosidase activity in cerebrospinal fluid as a marker of inflamatory processes in neurological diseases. J Lab Med (Berlin)(Berlin) 2001;25:77–81. [Google Scholar]
  • 15. Escott GM, Adams DJ. Chitinase activity in human serum and leukocytes. Infect Immun 1995;63:4770–4773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Boussac M, Garin J. Calcium‐dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000;21:665–672. [DOI] [PubMed] [Google Scholar]
  • 17. Casal JA, Chabas A, Tutor JC. Thermodynamic determination of β‐hexosaminidase isoenzymes in mononuclear and polymor‐phonuclear leukocyte populations. Am J Med Genet 2003;116:229–233. [DOI] [PubMed] [Google Scholar]
  • 18. Wakamatsu N, Kobayashi H, Miyatake T, Tsuji S. A novel exon mutation in the human β‐hexosaminidase β subunit gene affects 3′ splice site selection. J Biol Chem 1992;267:2406–2413. [PubMed] [Google Scholar]
  • 19. Newman DJ, Price CP. Renal function In: Burtis CA, Ashwood ER, editors. Tietz fundamentals in clinical chemistry. Philadelphia: WB Saunders Company; 2001. p 698–722. [Google Scholar]
  • 20. Houot O. Créatinine In: Siest G, Henny J, Schiele F, editors. References en biologie clinique. Paris: Elsevier; 1990. p 233–245. [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES